As a global leader in developing and delivering generic medicines, Sandoz has a comprehensive offering both geographically and in portfolio terms, plus a range of value-added customer and patient services. We offer a broad portfolio covering all major therapeutic areas, resulting in substantial savings for healthcare providers and improved access to healthcare.
Sandoz is a pioneer and a global leader in biosimilars – approved biologics with comparable quality, safety and efficacy to existing biologics that introduce competition which lowers costs. In addition, as a global leader in generic antibiotics, we play a critical role in ensuring the sustainability of global healthcare systems. Antibiotics are the cornerstone of healthcare today. In addition to treating a wide range of infectious diseases, antibiotics are critical to ensuring patient safety during medical procedures.
As well as being a global leader in biosimilars and generic antibiotics, dermatology and transplantation medicines, we hold leading global positions in areas ranging from generic cardiovascular, central nervous system, pain, ophthalmology, oncology and respiratory.
Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines. Our products, which are sold in more than 160 countries, reach approximately 500 million patients and our aspiration is to reach one billion.1 In the UK we delivered around 112 million packs of medicine in 2019.2